

# Journal Pre-proof

No impact of previous NRTIs resistance in HIV positive patients switched to DTG +2NRTIs under virological control: Time of viral suppression makes the difference.

Andrea Giacomelli, Alessia Lai, Marco Franzetti, Franco Maggiolo, Simona Di Giambenedetto, Vanni Borghi, Daniela Francisci, Giacomo Magnani, Monica Pecorari, Laura Monno, Ilaria Vicenti, Luciana Lepore, Francesca Lombardi, Stefania Paolucci, Stefano Rusconi, on behalf of ARCA collaborative group



PII: S0166-3542(19)30526-1

DOI: <https://doi.org/10.1016/j.antiviral.2019.104635>

Reference: AVR 104635

To appear in: *Antiviral Research*

Received Date: 10 September 2019

Revised Date: 14 October 2019

Accepted Date: 15 October 2019

Please cite this article as: Giacomelli, A., Lai, A., Franzetti, M., Maggiolo, F., Di Giambenedetto, S., Borghi, V., Francisci, D., Magnani, G., Pecorari, M., Monno, L., Vicenti, I., Lepore, L., Lombardi, F., Paolucci, S., Rusconi, S., on behalf of ARCA collaborative group, No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference., *Antiviral Research* (2019), doi: <https://doi.org/10.1016/j.antiviral.2019.104635>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier B.V.

**No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: time of viral suppression makes the difference.**

Andrea Giacomelli<sup>1,2</sup>, Alessia Lai<sup>2</sup>, Marco Franzetti<sup>3</sup>, Franco Maggiolo<sup>4</sup>, Simona Di Giambenedetto<sup>5,6</sup>, Vanni Borghi<sup>7</sup>, Daniela Francisci<sup>8</sup>, Giacomo Magnani<sup>9</sup>, Monica Pecorari<sup>10</sup>, Laura Monno<sup>11</sup>, Ilaria Vicenti<sup>12</sup>, Luciana Lepore<sup>11</sup>, Francesca Lombardi<sup>6</sup>, Stefania Paolucci<sup>13</sup>, and Stefano Rusconi<sup>1,2</sup> on behalf of ARCA collaborative group.

<sup>1</sup> III Infectious Disease Unit, ASST-FBF-Sacco, Milan, Italy

<sup>2</sup> Department of Biomedical and Clinical Sciences DIBIC L. Sacco, University of Milan, Milan, Italy

<sup>3</sup> UOC Infectious Disease Unit, ASST-Lecco, Lecco, Italy

<sup>4</sup> Department of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

<sup>5</sup> Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia, UOC malattie infettive

<sup>6</sup> Università Cattolica del Sacro Cuore, Roma Italia, Istituto di Clinica Malattie Infettive

<sup>7</sup> Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy.

<sup>8</sup> Clinical Infectious Diseases, University of Perugia, Perugia, Italy.

<sup>9</sup> Infectious Disease Unit, Reggio Emilia, Italy

<sup>10</sup> Unit of Virology and Molecular Microbiology, University Hospital, Modena, Italy.

<sup>11</sup> Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari, Italy

<sup>12</sup> Department of Medical Biotechnologies, University of Siena, Siena, Italy.

<sup>13</sup> Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS  
Policlinico San Matteo, Pavia, Italy.

Corresponding author

Andrea Giacomelli, M.D.

III Infectious Diseases Unit, DIBIC “Luigi Sacco”, University of Milan

Via G.B. Grassi, 74

20157 Milan, Italy

Phone +39.02.50319761

Fax +39.02.50319758

e-mail [andrea.giacomelli@unimi.it](mailto:andrea.giacomelli@unimi.it)

ORCID ID: 0000-0003-3685-4289

**Running title:** No impact of previous NRTIs resistance in the switch to DTG+2NRTIs

## Highlights

- The switch to DTG+2NRTIs appeared to be effective with 4% (95% CI 1.6-5.5) probability of virological failure at 12 months
- Previous NRTIs resistance does not affect the efficacy of switching to DTG+2NRTIs regimens
- Time of viral suppression before the switch to DTG+2NRTIs correlates with the risk of virological failure

**Abstract**

The accumulation of drug-resistance mutations on combined antiretroviral regimens (ART) backbone could affect the virological efficacy of the regimen. Our aim was to assess the impact of previous drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) on the probability of virological failure (VF) in patients, under virological control, who switched to dolutegravir (DTG)+2NRTIs regimens. All HIV-1 positive drug-experienced patients who started a regimen composed by DTG+2NRTIs [abacavir/lamivudine or tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)/emtricitabine (FTC)] in the ARCA collaborative group with HIV-RNA <50 cp/mL were included in the analysis. Patients with a previous VF to integrase inhibitors were excluded. The impact of single and combined NRTIs mutations on the probability of VF (defined as 2 consecutive HIV-RNA >50 copies/mL or one HIV-RNA >1,000 copies/mL) was assessed by Kaplan Meier curves. A multivariable Cox regression analysis was constructed to assess factors potentially related to VF. Five hundred and eighty-eight patients were included in the analysis with a median time of viral suppression before the switch of 37 months (IQR 12-78), of whom 148 (25.2%) had at least one previous NRTIs resistance mutation. In the multivariable model no association was observed between NRTIs mutations and VF. Conversely, the duration of viral suppression before switch resulted associated with a lower risk of VF (for 1 month increase, adjusted 0.98, 95%CI 0.96-0.99;  $p=0.024$ ). Previous NRTIs mutations appeared to have no impact on the risk of VF in patients switched to DTG+2NRTIs, whereas a longer interval on a controlled viremia decreased significantly the risk of VF.

**Key words:** Dolutegravir; drug resistance; genotypic resistance test; M184V/I; NNRTIs.

In the past decades antiretroviral therapy (ART) has dramatically changed the natural history of HIV-1 infection by transforming an invariably fatal disease into a chronic one [1]. The advent of a new class of antiretroviral, integrase inhibitors (INIs), has provided new effective and well tolerated ART options both in naïve [2-5] and experienced patients [6-7]. Simplification strategies based on INIs are increasingly used in clinical practice with the aim to improve the tolerability and to avoid potential long-term metabolic untoward effects of other antiretrovirals, i.e. boosted protease inhibitors (PIs) [8-10]. In the first simplification studies assessing the efficacy of INIs (SWITCHMRK and SPIRAL) the switch to raltegravir (RAL) was compared with maintaining PIs-based regimens. The inclusion criteria of both studies allowed the enrolment of patients with previous virological failure (VF) [11, 12]. In the SWITCHMRK, RAL based regimens failed to meet non inferiority when compared to boosted lopinavir containing regimens, with a not negligible percentage of patients developing resistance to RAL documented by the genotypic resistance test (GRT) [11]. Conversely, the SPIRAL study established the non-inferiority of RAL to PIs-containing regimens [12]. When compared to first generation INIs (i.e. RAL and elvitegravir), dolutegravir (DTG) presents a higher genetic barrier [13]. Nevertheless, due to the high rate of VF observed in the SWITCHMRK, patients with previous VF, with documented resistance to one of the investigated ART components, were subsequently excluded from the DTG switch studies [6, 7, 11]. Therefore, only data derived from observational studies are available regarding the potential impact of previous reverse transcriptase (RT) mutations on the virological efficacy of DTG triple therapy [14-16].

The aim of the present study was to assess the impact of previous drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) on the probability of VF in HIV-1 positive drug-experienced patients, with an undetectable HIV-RNA (<50cp/mL) and at least one previous GRT, who switched to a dolutegravir (DTG)+2 NRTIs regimen.

We performed a retrospective observational study using the Antiviral Response Cohort Analysis (ARCA) database (<https://www.dbarca.net/>), which prospectively collects data on HIV resistance and ART; at present, data from >41,000 patients in Italy are available [17]. The ARCA database was queried to retrieve the data of HIV-1-positive patients with (i) age  $\geq 18$  years, (ii) HIV-RNA  $\leq 50$  copies/mL at the time of the switch, (iii) subsequently switching to DTG + tenofovir/emtricitabine (TDF/FTC) or tenofovir alafenamide (TAF)/FTC or abacavir/lamivudine (ABC/3TC) for any reason, (iv) with at least 1 previous GRT, (v) with at least 1 virological and clinical follow-up after switching to DTG + 2NRTIs. Patients with a previous VF to INIs-containing regimens were excluded from the analysis.

The occurrence of any NRTIs mutation was determined using historical GRT; mutations were assessed by the Stanford list Version 8.7 update 2018-10-19 [18]. The mutations considered in the analysis were M184V/I, K65R, Q151M, the T69 insertion, the thymidine analogues mutations (TAM)-1 (M41L, L210W, and T215Y), TAM-2 (D67N, K70R, T215F, and K219Q/E) and cumulative TAM; moreover, any of these mutations in whatever previous GRT was considered as positive.

The primary end-point was to assess the impact of single and combined RT mutations in the historical GRT on the probability of VF (defined as 2 consecutive HIV-RNA  $> 50$  copies/mL or one HIV-RNA  $> 1,000$  copies/mL) after the switch to an antiretroviral regimen composed by DTG+TDF/FTC or TAF/FTC or ABC/3TC in patients with an HIV-RNA  $< 50$  copies/mL at the time of switching.

Standard survival analyses with Kaplan-Meier curves were used to analyse the probability of time to VF. Patients were followed from the switch to DTG+2NRTIs to the study outcomes, last available follow-up, or December 5, 2018, whichever occurred first.

Patients switching for any reason to an ART other than DTG+2NRTIs or loss to follow up were censored in the survival analysis.

To assess the predictors of VF a univariate and multivariable Cox proportional hazard model was built. The following variables were considered in the final model: age, gender, transmission route, concomitant use of ABC or TDF/TAF backbone, HIV-RNA zenit, CD4 cell counts nadir, number of previous antiretroviral lines, years on combined antiretroviral treatment, time of pre-switch viral suppression, the presence of K65R, M184V/I or 3 or more TAMs.

All analyses were performed using the SPSS v.22.0 software package. *P* values of less than .05 were considered significant.

The study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and later amendments. All patients signed an informed consent for use of their clinical and laboratory data in aggregated and anonymous form. Access to the database and data analyses were regulated by local institutional ethics committees and by Italian and European privacy legislation.

Five hundred and eighty-eight patients were included in the analysis, 423 (71.9%) of whom were males, with a median age of 51 years [Inter quartile range (IQR) 44-56] and 165 (28.1%) were receiving TDF or TAF/FTC. Patient's baseline characteristics at the time of the switch are reported in Table 1. Overall, the median number of previous regimens was 3 (IQR 1-6) and the median time of viral suppression before the switch was 31 months (IQR 12-78). One hundred and forty-eight patients (25.2%) presented at least one NRTIs mutations in their historical GRT, 102 (17.3) had the M184V/I mutation and 77 (13.1%) 3 or more TAMs.

The median time of observation was 12 months (IQR 6-19). During this time, 259 (44%) patients discontinued DTG+2NRTIs for any reason (20.8% were for toxicity, 13.1% for simplification, 15.9% for other reasons, 2.3% for VF and not reported for 47.9% of patients). Cumulative VF occurred in 19 (3.2%) subjects. At 12 months the overall probability of experiencing a VF was 4% [95% Confidence Interval (95% CI 1.6-5.5)].



According to the historical GRT, the probability of having a VF at 12 months in patients with or without any NRTIs mutation was 5% (95% CI 0.6-10.2) and 3% (95% CI 1-4.9) ( $p=0.635$ ), respectively. No difference was observed at 12 months in the rate of VF in patients harbouring or not in their historical GRT the M184V/I mutation [7% (95% CI 0.9-13.8) vs 3% (95% CI 0.9-4.5);  $p=0.420$ ] and 3 or more TAMs [5% (95% CI 0-12) vs 3% (95% CI 1.3-5.4);  $p=0.871$ ]. Moreover, no difference in the rate of VF failure was observed when combining M184V/I and K65R mutations ( $p=0.061$ ).

In the multivariable Cox proportional hazard model, after correcting for age, gender, risk factors, immune-virological status and years on ART, no significant association was observed between NRTIs mutations and VF. Conversely, the time of viral suppression before the switch resulted associated with a lower risk of VF [for 1 month increase, adjusted 0.98 (95% CI 0.96-0.99);  $p=0.024$ ] (Table 2).

Our study highlights the virological efficacy of DTG+2NRTIs combination therapy with only 3.2% of patients who discontinued the regimen due to VF during the time of observation. This finding is in line with the virological efficacy of DTG based regimens reported in observational studies with a mixed population of patients harbouring or not resistance to NRTIs [15, 16, 19].

In our study we observed no impact of previous NRTIs resistance according to the historical GRT on the risk of VF of ART composed by DTG+2 NRTIs. This finding is interesting because no information is available from randomized clinical trial due to the exclusion of patients with previous NRTIs mutations [6, 7]. Nevertheless, a recent large observational study conducted in several European countries confirmed the absence of the impact of M184V/I on the virological efficacy of ABC/3TC/DTG regimen in switch strategy [15]. Furthermore, the DAWNING study showed that, in patients failing their first antiretroviral regimen, DTG was superior to boosted lopinavir in obtaining virological suppression at 48 weeks [20]. Very recently, two Phase 3 TAF/FTC/bictegravir (BIC) switch studies (studies 1878 and 1844) demonstrated a high rate of

virological suppression at week 48 in the overall population and in subjects with pre-existing resistance, including M184V/I [21]. Taken together these results support the implementation of DTG or BIC-based ART in resource limited setting also in patients with previous VF to NRTIs containing regimens [22, 23].

In our study no association was observed between previous PIs exposure and the risk of VF, thereby supporting the findings reported by Chen et al. who evaluated patients switching from boosted PIs to DTG with or without previous NRTIs mutations [16]. These results highlight the high genetic barrier of DTG [13] and they might support the use of DTG-based ART as alternative regimens in simplification strategies from boosted PIs in patients with previous NRTIs resistance [6, 10]. Nevertheless, in our study we observed a high rate of DTG+2NRTIs treatment interruption due to any causes. Consequently, if on one hand we can infer about the virological efficacy of the DTG-containing regimen, on the other hand the tolerability of such regimen might be questioned, possibly due to central nervous system side effects and weight gain [24, 25].

In our study, we found an association between the time of pre-switch viral suppression and the risk of VF. The importance of the duration of viral suppression before the switch was highlighted by the different results of the first two switch trial of RAL, SWITCHMRK and SPIRAL [11, 12]. In the SWITCHMRK, a pre-switch time of viral suppression of more than 3 months was allowed, with approximately 18% of patients with less than one year of boosted lopinavir exposure before randomization, and the non inferiority of RAL-based regimens was not met [11]. On the contrary, in the SPIRAL study demonstrating the non inferiority of RAL, patients had a longer median time of viral suppression before the switch [67 months (IQR 59–73)] [12]. Moreover, in the study by Olearo et al, in which patients had a longer viral suppression than in our study before switching to ABC/3TC/DTG (134 months and 83.5 months in those with and without M184V/I vs 31 months, respectively), no impact of the time of viral suppression on VF was observed [15].

Our study has several limitations. First, the observational nature of the study could have affected the results due to missing or incomplete data. In particular, an intrinsic limitation in the dataset regards the reasons of DTG+2NRTIs discontinuation, thus challenging the inference about tolerability of such ART. Second, the high discontinuation rate and the median time of observation of only 12 months did not allow to assess the long term impact of NRTIs mutations. Third, a very few VFs were observed despite our conservative definition of VF, although in line with the rate reported in previous works [15, 16]. Finally, when considering the K65R mutation, a type 2 error cannot be excluded due to the low number of cases and consequently our findings should not be generalized to such patients.

According to our findings, the risk of VF after switching to DTG+2NRTIs appears to be low. Previous NRTIs mutations seem to have no impact on the risk of VF in patients under virological control on ART regimens based on DTG+2NRTIs. Moreover, a longer time of virological suppression before the switch resulted associated to a reduced risk of VF. Thus, caution should be warranted when considering the switch to DTG+2NRTIs in patients with a short time of viral suppression.

Table 1. Characteristic of the study population at time of the switch.

Journal Pre-proof

<b>Patients characteristics</b>	<b>Total n=588</b>
Gender, n (%)	
Male	423 (71.9)
Female	165 (28.1)
Median Age (yrs), (IQR)	51 (44-56)
Epidemiology, n (%)	
Sexual Risk	327 (55.6)
IDUs	109 (18.5)
Other	9 (1.6)
Unknown	143 (24.3)
Years on ART, median (IQR)	8 (4-17)
Number of previous ART regimens, median (IQR)	3 (1-6)
Months of viral suppression before switch, median (IQR)	31 (12-78)
CD4 cells nadir < 200 cell/ $\mu$ L, n (%)	302 (51.4)
HIV-RNA zenit cp/mL Log, median (IQR)	5.0 (4.4-5.6)
Previous AIDS events, n (%)	56 (9.5%)
Backbone, n (%)	
ABC	423 (71.9)
TDF/TAF	165 (28.1)
Switch from a PIs containing regimen, n (%)	323 (54.9)
HCV, n (%)	
Positive	145 (24.7)
Negative	234 (39.8)
Unknown	209 (35.5)
HBV, n (%)	
Positive	82 (14)
Negative	307 (52.2)
Unknown	199 (33.8)
Previous NRTIs resistance, n (%)	
M184V/I	102 (17.3)
K65R	6 (1.0)

---

3 or more TAMs	77 (13.1)
Any NRTIs mutation	148 (25.2)

---

List of abbreviations: n= number, yrs= years, IDUs= intravenous drug users, ABC= abacavir, TDF= tenofovir disoproxil fumarate, TAF= tenofovir alafenamide, PIs= protease inhibitors, NRTIs= nucleoside reverse transcriptase inhibitors, TAMs= thymidine analogues mutations.

Journal Pre-proof

Table 2. Uni and multivariable analysis of factors associated with VF after switching to DTG + 2 NRTIs.

	<b>HR</b>	<b>95% CI</b>	<b><i>p</i></b>	<b>aHR</b>	<b>95% CI</b>	<b><i>p</i></b>
Male vs Female	1.53	0.60-3.90	0.373	2.49	0.90-6.89	0.079
Age (per 1 year more)	0.99	0.95-1.04	0.798	0.99	0.94-1.05	0.767
IDUs vs Sexual Risk	2.75	1.03-7.30	0.043	2.65	0.73-9.57	0.137
Unknown vs Sexual Risk	1.09	0.29-4.11	0.900	1.36	0.32-5.88	0.685
ABC vs TDF/TAF	0.65	0.26-1.64	0.367	1.06	0.35-3.23	0.914
Zenit RNA (per 1 Log increase)	1.63	0.95-2.78	0.077	1.81	0.92-3.58	0.085
CD4 nadir <200 vs >200/mm <sup>3</sup>	0.84	0.34-2.06	0.699	0.56	0.20-1.55	0.265
Number of previous lines (per 1 more)	1.05	0.95-1.15	0.333	0.98	0.82-1.17	0.806
Years on cART (per 1 year more)	1.01	0.95-1.08	0.722	1.03	0.93-1.15	0.559
Time of viral suppression (per 1 month increase)	0.98	0.96-0.99	0.019	0.98	0.96-0.99	0.029
Switch from a PIs containing regimen	0.55	0.22-1.41	0.214	0.42	0.15-1.18	0.101
K65R mutation presence	5.14	0.68-38.90	0.112	3.23	0.27-38.40	0.352
3 or more TAMs presence	1.11	0.32-3.82	0.871	2.01	0.30-13.41	0.470
M184V/I mutation presence	1.52	0.55-4.21	0.424	0.99	0.19-5.21	0.986

List of abbreviations: HR= Hazard Ratio, aHR= adjusted Hazard Ratio, CI= Confidence Interval, IDUs= intravenous drug users, ABC= abacavir, TDF= tenofovir disoproxil fumarate, TAF= tenofovir alafenamide, PIs= protease inhibitors, TAMs= thymidine analogues mutations.

## **Acknowledgement**

We thank all the people involved in the ARCA collaborative study group.

## **Funding**

We report no financial support for the design and writing of this study.

## **Transparency declaration**

AG received consultancy fees from Mylan. SR received research grants to his Institution from ViiV Healthcare, Gilead Sciences and Janssen, outside the submitted work; he was also a paid consultant for ViiV Healthcare, Gilead Sciences, Merck Sharp and Dohme, Bristol-Myers Squibb, Janssen and Mylan.



**Bibliography**

1. Palella FJ Jr, Baker RK, Moorman AC, et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir Immune Defic Syndr* 2006; 43:27–34.
2. Raffi F, Jaeger H, Quiros-Roldan E, et al; extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis*. 2013 Nov;13(11):927-35.
3. Molina JM, Clotet B, van Lunzen J, et al; FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naïve adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. *Lancet HIV*. 2015 Apr;2(4):e127-36.
4. Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet HIV*. 2019 Jun;6(6):e355-e363.
5. Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. *Lancet HIV*. 2019 Jun;6(6):e364-e372.
6. Gatell JM, Assoumou L, Moyle G, et al; European Network for AIDS Treatment 022 (NEAT022) Study Group . Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed

- Patients With High Cardiovascular Risk or Age  $\geq 50$  Years: Final 96-Week Results of the NEAT022 Study. *Clin Infect Dis*. 2019 Feb 1;68(4):597-606.
7. Trottier B, Lake JE, Logue K, et al. Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. *Antivir Ther*. 2017;22(5):459-460.
  8. Raffi F, Esser S, Nunnari G, Pérez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. *HIV Med*. 2016 Oct;17 Suppl 5:3-16.
  9. Andreoni M, Marcotullio S, Puro V, et al. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. *New Microbiol*. 2015 Oct;38(4):443-90.
  10. Giacomelli A, Ranzani A, Oreni L, et al. Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects. *DRUG DESIGN, DEVELOPMENT AND THERAPY*. - ISSN 1177-8881. - Volume 13(2019 Jul), pp. 2271-2282.
  11. Eron JJ, Young B, Cooper DA et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. *Lancet* 2010; 375: 396–407.
  12. Martinez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. *AIDS* 2010; 24: 1697–1707.
  13. Kobayashi M, Yoshinaga T, Seki T, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. *Antimicrob Agents Chemother*. 2011;55(2):813–821.

14. Sörstedt E, Carlander C, Flamholz L, et al. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. *Int J Antimicrob Agents*. 2018 May;51(5):733-738.
15. Olearo F, Nguyen H, Bonnet F, et al. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients, *Open Forum Infectious Diseases*, , ofz330, <https://doi.org/10.1093/ofid/ofz330>
16. Chen GJ, Sun HY, Chang SY, et al. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. *Int J Antimicrob Agents*. 2019 Jul;54(1):35-42.
17. [www.dbarca.net](http://www.dbarca.net). Accessed 23 June 2019.
18. <https://hivdb.stanford.edu/hivdb/by-mutations/> Accessed 23 June 2019
19. Baldin G, Ciccullo A, Capetti A, et al. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study. *HIV Med*. 2019 Feb;20(2):164-168.
20. Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. *Lancet Infect Dis* 2019; 19:253–264.
21. Andreatta K, Willkom M, Martin R, et al. Switching to bicitegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral

- resistance including M184V/I. *J Antimicrob Chemother.* 2019 Aug 20. pii: dkz347. doi: 10.1093/jac/dkz347
22. Hamers RL. Dolutegravir for second-line antiretroviral therapy. *Lancet Infect Dis.* 2019 Mar;19(3):218-219.
23. Inzaule SC, Hamers RL, Doherty M, et al. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. *Lancet Infect Dis.* 2019 Jul;19(7):e246-e252.
24. Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. *HIV Med.* 2017 Jan;18(1):56-63.
25. Menard A, Meddeb L, Tissot-Dupont H, et al. Dolutegravir and weight gain: an unexpected bothering side effect? *AIDS.* 2017 Jun 19;31(10):1499-1500.